All questionsDrug interactions: Eliquis (apixaban) in nonvalvular atrial fibrillation3 questions · 3 sourcesDrug interactionsWhich drug interactions require an Eliquis dose reduction in atrial fibrillation?“Combined P-gp and Strong CYP3A4 Inhibitors: Inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or ritonavir). In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with combined P-gp and strong CYP3A4 inhibitors. Clarithromycin Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS.” (opens the source at this quote in a new tab)CopyFlag“For diltiazem, no dose adjustment of ELIQUIS is required” (opens the source at this quote in a new tab)CopyFlagNote: 10 mg twice daily is the initial dose for treatment of DVT and PE; the NVAF doses are 5 mg and 2.5 mg twice daily.Can Eliquis be taken with rifampin, carbamazepine, phenytoin, or St. John’s wort?“Combined P-gp and Strong CYP3A4 Inducers: Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban.” (opens the source at this quote in a new tab)CopyFlag“Apixaban is a substrate of both CYP3A4 and P-gp. Concomitant use with drugs that are combined P-gp and strong CYP3A4 inducers decreases exposure to apixaban [see Clinical Pharmacology (12.3)] which increases the risk for stroke and other thromboembolic events.” (opens the source at this quote in a new tab)CopyFlagCan Eliquis be taken with aspirin, clopidogrel, or NSAIDs?“Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.” (opens the source at this quote in a new tab)CopyFlag“In ARISTOTLE, concomitant use of aspirin increased the bleeding risk on ELIQUIS from 1.8% per year to 3.4% per year and concomitant use of aspirin and warfarin increased the bleeding risk from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.3%) use of dual antiplatelet therapy with ELIQUIS.” (opens the source at this quote in a new tab)CopyFlag